Literature DB >> 9466965

Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells.

A E Lovett-Racke1, J L Trotter, J Lauber, P J Perrin, C H June, M K Racke.   

Abstract

Although multiple sclerosis (MS) patients and healthy individuals have similar frequencies of myelin basic protein (MBP)-specific T cells, the activation state of these cells has not been well characterized. Therefore, we investigated the dependence of MBP-reactive T cells on CD28-mediated costimulation in MS patients, healthy controls, and stroke patients. MBP-reactive T cells from healthy controls and stroke patients failed to proliferate efficiently when costimulation was blocked using anti-CD28, consistent with a naive T cell response. In contrast, MBP-specific T cell proliferation was not inhibited, or was only partially inhibited when CD28-mediated costimulation was blocked in MS patients. Blockade of CD28 failed to inhibit tetanus toxoid-specific T cell proliferation in both the controls and MS patients, demonstrating that memory cells are not dependent on CD28-mediated costimulation. Limiting dilution analysis indicated that the frequency of MBP-reactive T cells was significantly decreased in healthy controls compared with MS patients when CD28-mediated costimulation was blocked. These data suggest that MBP-reactive T cells are more likely to have been activated in vivo and/or differentiated into memory T cells in MS patients compared with controls, indicating that these cells may be participating in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466965      PMCID: PMC508618          DOI: 10.1172/JCI1528

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Differential activation through the TCR-CD3 complex affects the requirement for costimulation of human T cells.

Authors:  M Kawaguchi; D D Eckels
Journal:  Hum Immunol       Date:  1995-06       Impact factor: 2.850

2.  Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis.

Authors:  L A Stone; P S Albert; M E Smith; C DeCarli; M R Armstrong; D E McFarlin; J A Frank; H F McFarland
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

3.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

4.  Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

Authors:  M K Racke; D E Scott; L Quigley; G S Gray; R Abe; C H June; P J Perrin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

5.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

6.  Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.

Authors:  M Croft; L M Bradley; S L Swain
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

7.  Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.

Authors:  P J Perrin; D Scott; L Quigley; P S Albert; O Feder; G S Gray; R Abe; C H June; M K Racke
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

8.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  J Zhang; S Markovic-Plese; B Lacet; J Raus; H L Weiner; D A Hafler
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

9.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions.

Authors:  A Windhagen; J Newcombe; F Dangond; C Strand; M N Woodroofe; M L Cuzner; D A Hafler
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein.

Authors:  K W Wucherpfennig; J L Strominger
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

View more
  83 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 2.  miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing.

Authors:  Mireia Guerau-de-Arellano; Hansjuerg Alder; Hatice Gulcin Ozer; Amy Lovett-Racke; Michael K Racke
Journal:  J Neuroimmunol       Date:  2011-11-09       Impact factor: 3.478

Review 3.  Immunopathogenesis of multiple sclerosis: MBP and beyond.

Authors:  E Meinl; R Hohlfeld
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

4.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 5.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 6.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

7.  miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis.

Authors:  Kristen M Smith; Mireia Guerau-de-Arellano; Stefan Costinean; Jessica L Williams; Arianna Bottoni; Gina Mavrikis Cox; Abhay R Satoskar; Carlo M Croce; Michael K Racke; Amy E Lovett-Racke; Caroline C Whitacre
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

8.  PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Authors:  Lindsay M Webb; Stephanie A Amici; Kyle A Jablonski; Himanshu Savardekar; Amanda R Panfil; Linsen Li; Wei Zhou; Kevin Peine; Vrajesh Karkhanis; Eric M Bachelder; Kristy M Ainslie; Patrick L Green; Chenglong Li; Robert A Baiocchi; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

9.  CD4+CD28- costimulation-independent T cells in multiple sclerosis.

Authors:  S Markovic-Plese; I Cortese; K P Wandinger; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

10.  Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.

Authors:  Javad Rasouli; Bogoljub Ciric; Jaime Imitola; Patricia Gonnella; Daniel Hwang; Kedar Mahajan; Elisabeth R Mari; Farinaz Safavi; Thomas P Leist; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.